High-power Holmium:Yag lithotripsy in bladder urolithiasis: Is it safe and effective? A combined clinical and experimental study.

High-power laser Ho:YAG laser bladder lithotripsy

Journal

Arab journal of urology
ISSN: 2090-598X
Titre abrégé: Arab J Urol
Pays: United States
ID NLM: 101562480

Informations de publication

Date de publication:
2024
Historique:
medline: 31 5 2024
pubmed: 31 5 2024
entrez: 31 5 2024
Statut: epublish

Résumé

To evaluate the efficacy and safety of Holmium: Yttrium-Aluminum-Garnet (Ho:YAG) laser in bladder lithotripsy using high-power settings > 100 W. A combined experimental and clinical study was conducted. The Quanta Cyber: Ho 150 with a 550 μm Quanta optical fiber was utilized in all set-ups. Ablation rates for soft and hard artificial stones were tested in vitro using 100 W and 20 W power settings. In the experiment, a porcine bladder was used. The optical fiber was inserted through a rigid cystoscope, whilst a K-type thermocouple was inserted in the bladder dome. The tested high-power settings were 152 W, 120 W and 105 W. In every trial, the lasing time was over 60 s. In the clinical study, 35 patients underwent transurethral high-power bladder lithotripsy. Laser settings were set between 100 W and 150 W. Stone mass (stone weight) was significantly lower after stone ablation independently of the stone type or the laser settings. Significantly higher mass decrease and ablation rate were detected in high-power compared to low-power settings. In the experiment, the highest temperature recorded was 32°C at 152 W. At 120 W and 105 W, the peak temperatures didn't reach 30°C. In the clinical study, a stone-free rate of 100% and a mean operative time of 43 ± 18 min were reported. All patients stayed in the hospital for one day except for one who presented minor hematuria. Additional complications did not occur. Ho:YAG laser lithotripsy > 100 W is an effective, fast and safe modality for the treatment of bladder calculi.

Identifiants

pubmed: 38818258
doi: 10.1080/20905998.2024.2304516
pii: 2304516
pmc: PMC11136465
doi:

Types de publication

Journal Article

Langues

eng

Pagination

145-151

Informations de copyright

© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Déclaration de conflit d'intérêts

No potential conflict of interest was reported by the author(s).

Auteurs

Konstantinos Pagonis (K)

Department of Urology, University of Patras, Patras, Greece.

Paraskevi Katsakiori (P)

Department of Urology, University of Patras, Patras, Greece.

Angelis Peteinaris (A)

Department of Urology, University of Patras, Patras, Greece.

Vasileios Tatanis (V)

Department of Urology, University of Patras, Patras, Greece.

Arman Tsaturyan (A)

Department of Urology, Erebouni Medical Center, Yerevan, Armenia.

Gabriel Faria Costa (G)

Department of Urology, Unidade Local de Saúde de Matosinhos, Matosinhos, Portugal.
Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.

Solon Faitatziadis (S)

Department of Urology, University of Patras, Patras, Greece.

Athanasios Vagionis (A)

Department of Urology, University of Patras, Patras, Greece.

Anastasios Natsos (A)

Department of Urology, University of Patras, Patras, Greece.

Kristiana Gkeka (K)

Department of Urology, University of Patras, Patras, Greece.

Mohammed Obaidat (M)

Department of Urology, University of Patras, Patras, Greece.

Theodoros Spinos (T)

Department of Urology, University of Patras, Patras, Greece.

Theofanis Vrettos (T)

Department of Anesthesiology and ICU, University of Patras, Patras, Greece.

Evangelos Liatsikos (E)

Department of Urology, University of Patras, Patras, Greece.
Department of Urology, Medical University of Vienna, Vienna, Austria.

Panagiotis Kallidonis (P)

Department of Urology, University of Patras, Patras, Greece.

Classifications MeSH